Form 4: Neumora CFO Granted 350,000 Stock Options

Neumora Therapeutics' Chief Financial Officer, Michael Lee Milligan, was granted 350,000 stock options with a $2.33 exercise price, vesting over four years.

Summary

• Michael Lee Milligan, Chief Financial Officer and Principal Accounting Officer of Neumora Therapeutics, Inc. (NMRA), was granted 350,000 stock options.
• The stock options have an exercise price of $2.33 per share.
• The grant date for these options, also referred to as the Vesting Commencement Date, is January 8, 2026.
• The options are set to expire on January 8, 2036.
• The vesting schedule dictates that 25% of the shares subject to the option will vest on the first anniversary of the Vesting Commencement Date (January 8, 2027).
• Following the initial vesting, 1/48th of the total number of shares will vest monthly thereafter.
• All 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date (January 8, 2030).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is a positive for aligning management incentives with shareholder interests, reflecting standard compensation practices. It's not a major market moving event but indicates stability in executive compensation strategy.

Positives

• The grant of 350,000 stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing value creation.
• The four-year vesting schedule encourages sustained performance and retention of key executive talent within the company.

Negatives

• Potential for future dilution of existing shares if all options are exercised, although this is a standard component of executive compensation packages.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned management incentives, but also potential future dilution upon exercise of the options.
• Employees: This executive compensation event may set a precedent or reflect the company's overall approach to incentivizing key personnel, though specific details for other employees are not provided.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation grant and does not provide new information that would fundamentally alter the investment thesis for Neumora Therapeutics. It reinforces management's long-term alignment but does not present a catalyst for a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

Neumora Therapeutics, NMRA, Stock Option, Executive Compensation, CFO, Michael Lee Milligan, SEC Form 4, Insider Transaction, Equity Grant